Creative Bioarray Releases ADCC/ADCP/CDC Assay Services to Determine the Activity of Antibody

March 23 11:17 2022
Creative Bioarray announced the release of its Antibody-Dependent Cellular Phagocytosis (ADCP) and Antibody-Dependent Cellular Cytotoxicity (ADCC) assay services to determine the activity of the antibody and complement against specified target cell lines.

New York, USA – March 22, 2022 – DDA platform, the mature division of Creative Bioarray, is dedicated to providing integrated drug discovery services to pharma, biotechnology companies, and academic institutions around the world. With years of pharmacological experience, Creative Bioarray develops the best screening equipment and cell models, as well as the latest innovations in drug discovery to deliver first-class results for clients. Recently, Creative Bioarray announced the release of its Antibody-Dependent Cellular Phagocytosis (ADCP) and Antibody-Dependent Cellular Cytotoxicity (ADCC) assay services to determine the activity of the antibody and complement against specified target cell lines.

With extensive experience from multiple projects, Creative Bioarray incorporates therapeutic antibody positive controls for popular targets and stringent QC standards during macrophage differentiation and maturation. In addition, Creative Bioarray offers fully validated ADCP reporter gene assays and a rigorous documentation system that meets IND filing requirements.

ADCC, CDC and ADCP assays are relatively complex experiments, and many factors play an important role in determining the success of the assay, such as the expression level of the target molecule on the surface of the target cell, the binding affinity of the antibody drug to the target molecule, and antibody drug IgG subclass etc. Creative Bioarray will conduct a comprehensive project evaluation and respond to potential project risks to the greatest extent possible.

Creative Bioarray’s ADCC assays can help understand whether a biologic binds to an antigen of interest, activates immune cells through its Fc receptors, initiates cell death, or determines whether an Fc silencing approach is working. The ADCC assay portfolio also includes alternative ADCC assays using engineered cell lines stably expressing the FcγRIIIa receptor to eliminate donor-specific variation and provide a viable solution for validating these complex assays.

With strong expertise in in vitro macrophage differentiation, combined with the custom method and readout options, Creative Bioarray ensures that phagocytosis assay designs are tailored to the customer. Additionally, Creative Bioarray provides a powerful platform that allows developers to identify and measure CDC activity on a range of targets. Creative Bioarray develops off-the-shelf solutions and also offers fully custom development for new targets.

“Creative Bioarray is always proud of providing our clients with unique, high-quality, unique and tailored comprehensive drug discovery services.” said Hannah Cole, the marketing director of Creative Bioarray, also added, “With the help of our unparalleled technology platform, Creative Bioarray delivers the most robust and consistent results while maintaining the potency and potency of your antibody candidates.”

About DDA platform

As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.

Media Contact
Company Name: Creative Bioarray
Contact Person: Hannah Cole
Email: Send Email
Phone: 1-631-386-8241
Country: United States
Website: https://dda.creative-bioarray.com